Prolotherapy Injection: Difference between revisions

Revision as of 13:58, 3 November 2021

This article is a stub.

This page or section deals with a topic that is not widely recognised or accepted.

Please use your clinical judgement and note that this is not necessarily standard practice in NZ.

See Hauser et al for a free open access systematic review from 2016. ^[1] The most commonly use agent is dextrose. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.

References

↑ Hauser et al.. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clinical medicine insights. Arthritis and musculoskeletal disorders 2016. 9:139-59. PMID: 27429562. DOI. Full Text.

Literature Review

Reviews from the last 7 years: review articles, free review articles, systematic reviews, meta-analyses, NCBI Bookshelf

Articles from all years: PubMed search, Google Scholar search.

TRIP Database: clinical publications about evidence-based medicine.

Other Wikis: Radiopaedia, Wikipedia Search, Wikipedia I Feel Lucky, Orthobullets,

[1] Hauser et al.. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clinical medicine insights. Arthritis and musculoskeletal disorders 2016. 9:139-59. PMID: 27429562. DOI. Full Text.

[1]

@@ Line 1: / Line 1: @@
 {{stub}}
+{{nonmainstream}}
 See Hauser et al for a free open access systematic review from 2016. <ref>{{#pmid:27429562}}</ref>
+The most commonly use agent is dextrose. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.
 ==References==